Quest Diagnostics (DGX) announced that its AAVrh74 ELISA assay, or CDx, has been granted Breakthrough Device Designation from the FDA. Breakthrough Device Designation is an FDA process designed to expedite the development and review of certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. The enzyme-linked immunosorbent in vitro diagnostic assay is for the semi-quantitative detection of antibodies, or IgG, to AAVrh74 capsid in human serum. The test is intended to be used in conjunction with other available clinical information as an aid to identify patients eligible for treatment with Sarepta Therapeutics’ (SRPT) ELEVIDYS (delandistrogene moxeparvovec-rokl), gene therapy for certain individuals with Duchenne muscular dystrophy. In addition, Quest and Sarepta announced an expanded collaboration under which Quest will develop one or more companion or complementary diagnostics in connection with Sarepta’s portfolio of investigational and on-market gene therapies.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics Declares Quarterly Cash Dividend
- Quest Diagnostics announces availability of the AD-Detect on questhealth
- Quest (NYSE:DGX) Stock Down Despite Beating Q2 Estimates
- Quest Diagnostics narrows FY23 adjusted EPS view to $8.50-$8.90 from $8.45-$8.95
- Quest Diagnostics Reports Second Quarter 2023 Financial Results; Updates Guidance for Full Year 2023